Brigatinib

證據等級: L5

預測適應症: 10 個

Brigatinib: From ALK-Positive NSCLC to Fibromatosis, Gingival

One-Sentence Summary

Brigatinib (ALUNBRIG™) is a next-generation anaplastic lymphoma kinase (ALK) inhibitor approved globally for ALK-positive metastatic non-small cell lung cancer (NSCLC), though it is not currently registered in Singapore. The TxGNN model ranks Fibromatosis, Gingival as its top predicted new indication (score: 99.89%), but no clinical trials or supporting literature exist for this direction, and the mechanistic link is considered implausible. Across all 10 predicted indications, the most clinically actionable signals are concentrated in ALK-driven lung tumour subtypes and NF2-related schwannomatosis (rank 10), where emerging clinical evidence of tumour shrinkage with brigatinib has been reported.

Quick Overview

Item	Content
Original Indication	ALK-positive metastatic NSCLC (global FDA/EMA approval; no Singapore HSA registration)
Predicted New Indication	Fibromatosis, Gingival
TxGNN Prediction Score	99.89%
Evidence Level	L5
Singapore Market Status	Not marketed
Number of Registrations	0
Recommended Decision	Hold

Why Is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on published literature, Brigatinib is a next-generation small-molecule tyrosine kinase inhibitor with potent activity against ALK, ROS1, EGFR, and FLT3 — including mutation variants that confer resistance to the first-generation inhibitor crizotinib. It received FDA accelerated approval in April 2017 for crizotinib-refractory ALK-positive NSCLC, and full regulatory approval in 2020 based on the pivotal Phase 3 ALTA-1L trial, which demonstrated superior progression-free survival versus crizotinib in ALK inhibitor-naive advanced NSCLC patients. Outside its primary indication, preclinical and early clinical data suggest brigatinib also inhibits FAK and ErbB2, opening potential activity in NF2-driven tumours.

Gingival fibromatosis is a rare benign condition characterised by progressive fibrous overgrowth of gum tissue. Its established molecular drivers — SOS1 mutations, PTCH1 mutations, and TGF-β pathway dysregulation — bear no known relationship to the kinase targets of Brigatinib. There is no established biological pathway connecting ALK/ROS1/EGFR inhibition to gingival fibrous proliferation, and no plausible shared signalling mechanism has been proposed in the literature.

The TxGNN score of 99.89% for this indication most likely reflects a topological proximity artefact in the knowledge graph rather than a genuine pharmacological signal. The evidence pack explicitly categorises this as a probable false positive. No clinical trials have been initiated and no relevant literature exists. This prediction should not be prioritised for further investigation without new mechanistic evidence.

Clinical Trial Evidence

Currently no related clinical trials registered for Brigatinib in fibromatosis, gingival.

Literature Evidence

Currently no related literature available for Brigatinib in fibromatosis, gingival.

Singapore Market Information

Brigatinib is not currently registered with the Health Sciences Authority (HSA) in Singapore. No product licences are on record.

Cytotoxicity

Brigatinib is an antineoplastic agent (targeted therapy for ALK-positive malignancy). The following applies:

Item	Content
Cytotoxicity Classification	Targeted therapy — next-generation ALK/ROS1/EGFR tyrosine kinase inhibitor (TKI); not a conventional cytotoxic
Myelosuppression Risk	Low (less myelosuppressive than conventional chemotherapy; anaemia and lymphopenia reported in Phase 3 trials at low frequency)
Emetogenicity Classification	Low (oral agent; nausea reported in approximately 24% of patients, typically grade 1–2)
Monitoring Items	Pulmonary function (early pulmonary adverse events occur within the first 7 days in 3–9% of patients — a brigatinib-specific signal requiring close monitoring); liver enzymes (ALT/AST); CPK; lipase/amylase; blood pressure; fasting blood glucose; QTc interval
Handling Protection	Standard oral antineoplastic handling precautions apply

Safety Considerations

Please refer to the package insert for safety information. No HSA-registered product data or Singapore-specific warnings are currently available. Note: a fatal tumour lysis syndrome case following brigatinib initiation after sequential ALK inhibitor therapy has been reported in the literature (PMID 34987411) and represents a rare but serious safety signal to be aware of in heavily pre-treated patients.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN top prediction of gingival fibromatosis is biologically implausible — Brigatinib's ALK/ROS1/EGFR kinase inhibition profile has no established intersection with the SOS1/PTCH1/TGF-β drivers of gingival fibromatosis, and the high prediction score is consistent with a knowledge-graph topological artefact rather than a pharmacological signal.

To proceed, the following is needed:

Retrieve MOA data from DrugBank (DB12267) to enable full mechanistic analysis across all 10 predicted indications
Obtain the package insert from the FDA, EMA, or PMDA to populate Singapore-specific safety warnings, contraindications, and drug interaction data
Re-classify ALK+ NSCLC anatomical subtypes: Lung hilum carcinoma (rank 4) and pulmonary sulcus neoplasm (rank 8) should not be treated as novel indications — if ALK rearrangement is confirmed, both fall within the established ALTA-1L NSCLC framework and should be evaluated accordingly
Escalate NF2-related schwannomatosis (currently mapped under rank 10 with an incorrect disease label): PMID 38904277 (NEJM 2024) demonstrates clinical tumour shrinkage with brigatinib in NF2-SWN patients via FAK/ErbB2 inhibition; once correctly re-labelled, this indication qualifies for an L3 evidence review and warrants a dedicated repurposing assessment
Evaluate Singapore registration strategy for the established ALK+ NSCLC indication: Brigatinib is currently unregistered in Singapore despite strong Phase 3 ALTA-1L support and approvals in the US, EU, and Japan — this may represent an unmet access gap
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.